| Abstrakt: |
Researchers from the University of Miami Miller School of Medicine have conducted studies on Mantle Cell Lymphoma, focusing on tumor-vessel interactions and the effects of inhibiting these interactions using an antibody fusion protein called aCD20-EndoP125A. The research found that this protein inhibited lymphoma vessel co-option, angiogenesis, and lymphangiogenesis, leading to a reduction in tumor growth and dissemination. This novel therapeutic approach shows promise in inhibiting lymphoma progression and dissemination. For more information, the full article can be accessed for free at the Cells journal website. [Extracted from the article] |
